Santarus

We are a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians. Our current products are immediate-release formulations of omeprazole, a widely prescribed proton pump inhibitor, or PPI. PPIs are the most frequently prescribed drugs for the treatment of many upper gastrointestinal, or GI, diseases and disorders. We currently market ZEGERID® (omeprazole/sodium bicarbonate) Capsules and ZEGERID (omeprazole/sodium bicarbonate) Powder for Oral Suspension. These products are the first and only immediate-release oral PPIs approved by the U.S. Food and Drug Administration, or FDA, for commercial sale in the U.S. (see Products for more information). ZEGERID Capsules and ZEGERID Powder for Oral Suspension are being marketed in the U.S. by a field sales force of over 500 sales representatives who promote ZEGERID products in the primary detail position. Our sales force presence includes approximately 210 of our own field sales representatives and 170 field sales representatives under a co-promotion agreement with Otsuka America Pharmaceutical, Inc. In addition, our field sales force presence increased in early 2007 with the addition of approximately 140 contract sales representatives from inVentiv Commercial Services, LLC. The ZEGERID sales force calls on approximately 26,000 gastroenterologists and primary care physicians who are among the highest prescribing U.S. physicians for PPIs. In 2006 we reported net product sales of approximately $46 million, compared to 2005 net product sales of $13.7 million. These sales results were accomplished with only nine months of capsules sales and ZEGERID Capsules have quickly become our primary product offering. Our stock trades on the NASDAQ Global Market under the symbol "SNTS".

Contact Details: 10590 West Ocean Air Drive Suite 200 San Diego CA 92130 United States of America Tel: 858-314-5700 Fax: 858-314-5701 Email: contact@santarus.com WWW: www.santarus.com/

Loading...

BioNews Results for Santarus:
Santarus to Hold Second Quarter 2008 Financial Results Conference Call on August 4	Pharma Live:  Jul 17 2008 12:52PM Matching: santarus
Santarus to Hold Second Quarter 2008 Financial Results Conference Call on August 4	Genetic Engineering News:  Jul 17 2008 8:49AM Matching: santarus
Santarus Increases Revolving Line of Credit to $25 Million and Extends Maturity to July 2011	Genetic Engineering News:  Jul 14 2008 9:38AM Matching: santarus
Santarus Increases Revolving Line of Credit to $25 Million and Extends Maturity to July 2011	Pharma Live:  Jul 14 2008 9:01PM Matching: santarus
Abbott Clears Key FDA Hurdle for New Artery Device	San Diego Business Journal:  Jul 11 2008 4:35PM Matching: santarus
Promote your company here: BioNewsCast - Press Release Distribution	→View more Santarus news.

Santarus (SNTS) Financial information Links from Barchart
SNTS Quote from from Barchart.com
SNTS Chart from from Barchart.com
SNTS Profile from from Barchart.com
SNTS Opinion from from Barchart.com
→View more Santarus finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 367 times since April 2007, the link to the organisation's website has been followed 76 times

Recent Search Terms used to find this page: santarus pharma sales force | santarus | omeprazole | santarus pharmaceutical 10590 west ocean air drive san diego ca | santarus agreements | Santarus pharma contact details | Santarus | santarus | santarus.com | Santarus | .

Search for more companies in San Diego

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Santarus